ENTRADA THERAPEUTICS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-08: Study NCT07682129; Company role Lead sponsor; Phase Phase 2; Status Not yet recruiting.
- 2025-08-30: Study NCT07038824; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Recruiting.
- 2025-06-30: Study NCT07037862; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Recruiting.
- 2020-08-06: Study NCT04245917; Company role Lead sponsor; Phase Observational; Status Suspended.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-08 | NCT07682129 Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) | Lead sponsor | Phase 2 | Not yet recruiting | Duchenne Muscular Dystrophy (DMD) | 80 | 2032-03 |
| 2025-08-30 | NCT07038824 A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | Lead sponsor | Phase 1, Phase 2 | Recruiting | Duchenne Muscular Dystrophy (DMD) | 24 | 2029-03-01 |
| 2025-06-30 | NCT07037862 A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | Lead sponsor | Phase 1, Phase 2 | Recruiting | Duchenne Muscular Dystrophy (DMD) | 24 | 2029-03-28 |
| 2020-08-06 | NCT04245917 Natural History Study of MNGIE | Lead sponsor | Observational | Suspended | Mitochondrial Neurogastrointestinal Encephalomyopathy | 60 | 2026-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |